Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Biorxiv : the Preprint Server for Biology|August 6, 2025
A novel sweeping antibody exhibits efficient clearance of the cancer- and autoimmunity-associated cytokine interleukin 16Jillian M Baker, Alexander Wang, Kenneth A Dietze, et al.
Biorxiv : the Preprint Server for Biology|June 25, 2024
Cathepsin B causes trogocytosis-mediated CAR T cell dysfunctionKenneth A Dietze, Kiet Nguyen, Aashli Pathni, et al.
Biorxiv : the Preprint Server for Biology|February 19, 2024
Restricting CAR T Cell Trafficking Expands Targetable Antigen SpaceErin A Morales, Kenneth A Dietze, Jillian M Baker, et al.
Cytotherapy|February 10, 2024
A novel multicolor fluorescent spot assay for the functional assessment of chimeric antigen receptor (CAR) T-cell productsDjordje Atanackovic, Thierry Iraguha, Destiny Omili, et al.
Signal Transduction and Targeted Therapy|April 22, 2026
Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell functionKenneth A Dietze, Kiet Nguyen, Aashli Pathni, et al.
Science Translational Medicine|July 19, 2023
Systematic single amino acid affinity tuning of CD229 CAR T cells retains efficacy against multiple myeloma and eliminates on-target off-tumor toxicityErica R Vander Mause, Jillian M Baker, Kenneth A Dietze, et al.
Human Vaccines & Immunotherapeutics|June 6, 2023
Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD)Kathryn Kline, Wengen Chen, Michael E Kallen, et al.
Cancer Immunology, Immunotherapy : CII|February 13, 2024
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cellsKathryn Kline, Tim Luetkens, Rima Koka, et al.
Haematologica|October 16, 2025
CNS infiltration by zamtocabtagene autoleucel tandem CD20/CD19 CAR T cells leading to complete remission in a patient with primary CNS lymphomaNancy M Hardy, Jean A Yared, Tim Luetkens, et al.
Nature Communications|July 3, 2025
Immune correlates of anti-BCMA CAR-T products idecabtagene vicleucel and ciltacabtagene autoleucel in a real-world cohort of patients with multiple myelomaDjordje Atanackovic, Tim Luetkens, Dina Schneider, et al.
Pageof 1